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Experimental models of inﬂammatory bowel diseases have
provided valuable insights into the complex mechanisms
operative in the development and pathogenesis of these
diseases. This review describes widely used models and
how they help us understand the immunology of intestinal
inﬂammation.
The understanding of the intestinal inﬂammation occur-
ring in the inﬂammatory bowel diseases (IBD) has been
immeasurably advanced by the development of the now
numerous murine models of intestinal inﬂammation. The
usefulness of this research tool in IBD studies has been
enabled by our improved knowledge of mucosal immunity
and thus our improved ability to interpret the complex
responses of mice with various causes of colitis; in addi-
tion, it has been powered by the availability of models in
which the mice have speciﬁc genetic and/or immunologic
defects that can be related to the origin of the inﬂamma-
tion. Finally, and more recently, it has been enhanced by
our newly acquired ability to deﬁne the intestinal micro-
biome under various conditions and thus to understand
how intestinal microorganisms impact on inﬂammation. In
this brief review of murine models of intestinal inﬂam-
mation, we focus mainly on the most often used models
that are, not incidentally, also the models that have yielded
major insights into IBD pathogenesis. (Cell Mol Gastro-
enterol Hepatol 2015;1:154–170; http://dx.doi.org/10.1016/
j.jcmgh.2015.01.006)Keywords: Cell Transfer Colitis; DSS Colitis; IL10 Deﬁciency;
Murine Colitis Models; NKT Cells; Oxazolone Colitis; TNBS
Colitis; TH1 Cells; TH17 Cells; Tregs.
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mation about mucosal immunology, particularly as the latter
relates to the maintenance of intestinal homeostasis or the
disruption of such homeostasis and the intestinal inﬂam-
mation encountered in the inﬂammatory bowel diseases
(IBD). No single model captures the complexity of human
IBD, but each model provides valuable insights into one or
another major aspect of disease, and together they have led
to the establishment of now a generally accepted set of
principles of human IBD pathogenesis. Chief among these
are that (1) different causes of induced or genetically based
inﬂammation give rise to a ﬁnite number of commonpathways of immunopathogenesis; (2) normal resident gut
microbiota can drive intestinal inﬂammation; (3) loss of oral
tolerance and disruption of the epithelial barrier contribute
to the development of intestinal inﬂammation; and (4)
polarized T helper (TH) cell responses as well as defects in
innate immunity mediate disease. In this review, we focus
on selected experimental models of intestinal inﬂammation
that amply verify these principles and in doing so provide
important contributions to our understanding of the im-
mune dysregulation that characterizes IBD. In addition, we
provide a brief summary (Table 1) of less common mouse
models that are based on genetic defects that lead to
increased susceptibility to gut inﬂammation.
DSS Colitis
Disruption of the intestinal epithelial barrier and thereby
the entry of luminal bacteria or bacterial antigens into the
mucosa has been clearly established as a disease mechanism
in enterocolitis by the fact that intestinal inﬂammation can be
more easily induced or may occur spontaneously in
numerous murine models characterized by molecular ab-
normalities that cause massive barrier loss. The importance
of an intact epithelium in the prevention of mucosal inﬂam-
mation was initially demonstrated by Hermiston and Gor-
don1 in an inﬂuential study published in the 1990s. In this
study, a chimeric mouse was created in which small intestinal
epithelial cell adhesion mediated by E-cadherin was under-
mined by the introduction of an epithelial cell transgene
expressing dominant negative N-cadherin. The small in-
testines of these mice contained patches of villi with poorly
adherent and incompletely differentiated transgenic enter-
ocytes adjacent to patches of normal enterocytes with normal
adherence. The striking ﬁnding was that inﬂammation
occurred in the lamina propria of these mice but only in areas
subjacent to the defective epithelium, strongly suggesting
that entry of commensal microorganisms into an otherwise
normal lamina propria can induce an inﬂammatory response.
Table 1.Experimental Models of Inﬂammatory Bowel Disease Due to Speciﬁc Genetic Defects
Model Underlying Defect Major Consequences Signiﬁcance
Muc2
Colitis147,148 Deﬁciency of Muc2, the main gastrointestinal
mucin.
Spontaneous colitis (severe in the distal colon) that
is enhanced by DSS administration and
develops into colorectal cancer. Inﬂammation is
associated with increases in intestinal
lymphocytes, TNF-a, and IL-1b.
Loss of epithelial barrier function resulting from
Muc2 deﬁciency causes inﬂammation.
Related models149,150 Lack of C3GnT (b1,3-N-
acetylglucosaminyltransferase), an enzyme
involved in the synthesis of core 3-derived
O-glycans that are components of colonic
mucins.149
Increased susceptibility to DSS colitis and DSS/
AOM-induced tumorigenesis; TH1 and TH7
proinﬂammatory cytokine production is
elevated.
Enhanced intestinal permeability due to deﬁciency
in core 3-derived O-glycans and reduced Muc2
levels increases susceptibility to colitis and
colorectal cancer.
Targeted deletion of core 1-derived O-glycans,
also components of mucins.150
Spontaneous colitis (severe in the distal colon and
rectum) driven by TNF-a-producing
macrophages and granulocytes rather than
lymphocytes. Inﬂammation is independent of
TLR signaling.
Core 1-derived O-glycans deﬁciency leading to a
reduced inner mucus layer and decreased
Muc2 enhances intestinal permeability to both
proteins and bacteria and causes inﬂammation,
that is associated with epithelial cell expression
of the Tn antigen, observed in some UC
patients.
MDR1a colitis151 Lack of P-gp, the product of the MDR1a gene
alters epithelial barrier function.
Spontaneous colitis driven by TH1 cytokines. A barrier defect arising from P-gp deﬁciency
causes increased intestinal permeability and
translocation of bacteria into the lamina propria,
and the development of colitis.152,153
TRUC model122 Disruption of the transcriptional regulator T-bet
in the innate immune system of RAG2/
mice.
Spontaneous colitis driven by intestinal ﬂora and
increased production of TNF-a and IL-23.
Cohousing of TRUC mice with wild-type mice
demonstrate transmission of colitis to a normal
host and thus reveal the existence of a
“colitogenic” microﬂora (such as Proteus
mirabilis and Klebsiella pneumonia or
Helicobacter typhlonius).154
First and only demonstration of the existence of a
colitogenic intestinal microﬂora. However,
treatment of TRUC mice with anti-TNF-a
therapy prevents inﬂammation and bacterial
populations from becoming “colitogenic,”
indicating that the development of the latter
requires an abnormal mucosal immune system.
NEMO
Colitis155 Intestinal epithelial cell-speciﬁc disruption of NF-kB
function via targeted deletion of NEMO, an
essential regulatory subunit of NF-kB also known
as IKK-g.
Spontaneous and severe chronic intestinal
inﬂammation.
Lack of NF-kB signaling results in heightened TNF-
a sensitivity and apoptosis of colonic epithelial
cells followed by inﬂammation caused by
translocation of bacteria into the mucosa.
Highlights role of TNF-a in maintenance of
epithelial cell barrier function.
Related model156 Speciﬁc deletion of the catalytic subunit of IKK-b in
intestinal epithelial cells.
Severe intestinal inﬂammation after infection with
the gut-dwelling parasite Trichuris muris and
reduced expression of TSLP.
IKK-b in intestinal epithelial cells promotes TH2-cell












Model Underlying Defect Major Consequences Signiﬁcance
SAMP1/Yit mouse157 The SAMP1/Yit strain was established by selective
breading of SAM (senescence accelerated mouse
derived from AKR/J mice) P1 strain mice showing
spontaneous skin ulcerations.
Spontaneous inﬂammation of the terminal ileum
and caecum driven by a TH1 response;
however, a TH2 response may develop at later
stages of disease. Exhibit “skip lesions.”
Inﬂammation originates from epithelial barrier
defect.
One of the few models exhibiting severe
inﬂammation of the terminal ileum, the primary
location of Crohn’s disease lesions.
XBP1 model158,159 Epithelial cell-speciﬁc deletion of the transcription
factor, XBP1, an important component of the ER
stress response.
Spontaneous enteritis and enhanced susceptibility
to DSS colitis.
Induction of ER stress through disruption of XPB1
causes small intestinal inﬂammation possibly
due to absence of Paneth cell antibacterial
mediators and reduction of goblet cells.
STAT3
Colitis160,161 Macrophage/neutrophil-speciﬁc deﬁciency of the
transcriptional regulator STAT3.
Spontaneous chronic enterocolitis associated with
a polarized TH1 response dependent on
overproduction of IL-12p40. Defective IL-10
signaling in macrophages.
IL-10 signaling in macrophages and neutrophils is
necessary to prevent abnormal regulation of
responses to the normal microﬂora.
Related model (IL-22
deﬁciency)162
Targeted deletion of STAT3 in intestinal epithelial
cells and associated IL-22 deﬁciency.
Enhanced susceptibility to DSS colitis. In intestinal epithelial cells, STAT3 activity is critical
for mucosal wound healing mediated by IL22
during acute colitis.
IL-7 transgenic mice163 Systemic overexpression of IL-7. Spontaneous chronic colitis associated with a
TH1 response.
IL-7 acts as a critical survival factor for colitogenic
CD4þ effector memory T cells.164 Bone marrow
is the main source of IL-7 and a substantial
population of colitogenic CD4þ memory T cells
reside in the bone marrow.165–168
Note: AOM, azoxymethane; DSS, dextran sulfate sodium; ER, endoplasmic reticulum; Foxp3, forkhead box P3; IBD, inﬂammatory bowel disease; IKK, IkB kinase; IL,
interleukin; MDR1a, multidrug resistance protein 1; Muc2, mucin 2; NEMO, NF-kB essential modulating protein; NF-kB, nuclear factor kB; P-gp, P-glycoprotein; TH, T
helper cell; TLR, Toll-like receptor; TNF-a, tumor necrosis factor-a; TSLP, thymic stromal lymphopoietin; STAT3, signal transducer and activator of transcription 3; TRUC,













Figure 1. Mechanism of dextran sulfate sodium (DSS) colitis. DSS colitis is most essentially a colitis due to loss of epithelial
barrier function and entry of luminal organisms or their products into the lamina propria. Such entry results in stimulation of
innate and adaptive lymphoid elements and secretion of proinﬂammatory cytokines and chemokines. In addition, it results in
the inﬂux of cells with cytotoxic potential such as neutrophils and inﬂammatory macrophages.
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(DSS) colitis, but in this case a sulfated polysaccharide that
is directly toxic to colonic epithelium causes epithelial cell
injury and the resulting immune responses alter mucosal
barrier function throughout the colonic epithelium
(Figure 1). Thus, administration of DSS to mice in their
drinking water for a short period of time results in the
induction of a very reproducible acute inﬂammation limited
to the colon and characterized by erosions/ulcers, loss of
crypts, and inﬁltration of granulocytes.2,3 Importantly, this
inﬂammation develops in the absence of T cells mediating
adaptive immunity, such as in SCID4 and Rag1/ mice,5
indicating that effector cytokines produced by innate cells
are sufﬁcient to cause the inﬂammation. On this basis,
DSS colitis has become a useful model for the study of the
innate immune mechanisms involved in the development of
intestinal inﬂammation; indeed, multiple studies have
highlighted the critical roles that innate cells such as mac-
rophages and neutrophils play in mucosal inﬂammation.4–9
This has led to the insight that macrophages are im-
portant sources of proinﬂammatory cytokines as well as
cytokines that regulate epithelial barrier function and pro-
liferation and that neutrophils are important contributors to
tissue damage.
In a related vein, DSS colitis has been used to explore the
role of innate immune mechanisms in colitis induction such
as those initiated by Toll-like receptors (TLR) and dectin
receptors or inﬂammasome stimulation.6,7,10–16 An impor-
tant ﬁnding here was the discovery that mice with gene
deletions affecting TLR signaling such as Tlr2/, Tlr4/,
and Myd88/ exhibit exacerbation of DSS colitis because
the signaling in epithelial cells and macrophages that de-
pends on these innate signaling components promotes
epithelial proliferation and epithelial barrier restoration and
limits bacterial translocation and inﬂammation.6,10,11
Therefore, the ability of these effectors to promote resto-
ration of epithelial function is even more important to thedevelopment of inﬂammation than their effect on produc-
tion of effector cytokines. TLR4/MyD88 signaling is also
required for neutrophil recruitment to the damaged mucosa,
as DSS-treated TLR4/MyD88 knockout mice exhibit a
decrease in neutrophil inﬁltrates due to reduced chemokine
expression by macrophages and diminished chemotactic
response by neutrophils.6 Furthermore, MyD88 signaling in
macrophages has been found to support and promote pro-
liferation and survival of colonic epithelial progenitors
thereby facilitating efﬁcient repair responses after DSS
injury.7
Because the primary lesion in DSS colitis involves
disruption of the epithelium, it lends itself to the study of
factors that maintain or reestablish the integrity of the
epithelium during or after injury. Many of these studies
have centered on the effects of TLR and cytokine stimula-
tion and have shown that factors derived from hemato-
poietic cells as well as factors derived from the epithelial
cells themselves affect integrity. With respect to TLR
stimulation, TLR2 ligand administration lessens the
severity of DSS colitis whereas TLR2-deﬁciency enhances
severity of DSS colitis. These observations can be explained
in part by the effects of TLR2 ligand stimulation of the
epithelial cell barrier function or epithelial cell apoptosis
and in part by the ability of TLR2 to induce anti-
inﬂammatory interleukin-10 (IL-10) production.11 In
addition, activation of epithelial TLR4 can lead to the
release of factors that have positive effects on epithelial cell
growth and reduce the severity of DSS colitis.17 This model
has been used to show that granulocyte-macrophage col-
ony-stimulating factor and IL-33 released by epithelial cells
(and other nonhematopoietic cells) have positive and
negative effects on epithelial cell renewal, respectively.18,19
Yet another focus of studies of epithelial reconstitution in
DSS colitis is the role of various intracellular signaling
pathways in such reconstitution. An interesting example of
the latter type of study is one showing that inhibition of the
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cell renewal during DSS colitis.20
Any discussion of the use of DSS colitis must also
mention the series of studies in which this model has
been applied to the evaluation of NLRP3 inﬂammasome
responses because this TLR-activated innate immune
mechanism results in the secretion of IL-1b and IL-18, two
cytokines with potential effects on epithelial cell integrity.
However, the outcome of inﬂammasome responses in DSS
colitis has proven to be unexpectedly complex. The reason
this might be is that while IL-1b is clearly a key proin-
ﬂammatory cytokine in DSS colitis,21–24 the function of
IL-18 is somewhat ambiguous. Thus, whereas initial work
concluded that IL-18 is required for induction of DSS
colitis,21,25,26 later work showed that a deﬁciency in NLRP3
inﬂammasome activity and production of IL-18 as well as a
defect in IL-18 signaling increases susceptibility to DSS
colitis.13,14,27–29 In all likelihood, the basis of these ﬁndings
is that, as noted herein, IL-18 has an important direct or
indirect role in epithelial cell restitution and repair after
injury.29,30
The DSS colitis model has also been used extensively to
study colon cancer developing in relation to colonic
inﬂammation, such as that occurring in patients with long-
standing ulcerative colitis.31–33 For such study, mice are
administered a single dose of azoxymethane, a genotoxic
colonic carcinogen that gives rise to colon adenomas or
carcinomas but only when such administration is followed
by induction of DSS colitis or another type of chronic co-
litis.34 The mechanism of neoplastic development in this
model is not yet completely understood. However, it is
likely that a simple initiator-promoter model, with azoxy-
methane serving as the initiator and the repair after cycles
of DSS-induced injury serving as the promoter, is involved.
One contributing factor to the development of cancer in
this model may be that the neutrophils produce large
amounts of IL-1b, which leads to macrophage and den-
dritic production of IL-6, a cytokine that acts as a tumor
promoter.35 IL-18 also comes into the picture here because
IL18/ and Il18r1/ mice display increased suscepti-
bility to DSS colitis neoplasia.29 This effect of IL-18 may be
channeled through IL-22 and IL-22bp (binding protein),
the latter a decoy protein that neutralizes IL-22. This
possibility arises from the fact that, on the one hand, the
interplay between IL-22 and IL-22bp has been shown to
impact epithelial cell growth and repair and thus control
tumorigenesis in the colon, and, on the other hand, these
factors are regulated by IL-18 and the NLRP3 or NLRP6
inﬂammasomes.30
Finally, and more recently, DSS colitis has provided a
platform for the investigation of the effects of the gut
microbiome on colitis development. This is exempliﬁed by
studies demonstrating that the NOD2 abnormalities give
rise to mice that develop changes in susceptibility to DSS
colitis and that the latter is associated with (or perhaps
caused by) changes in the gut microbiome.22,36 In addition,
it has been shown that mice deﬁcient in NLRP6, an
inﬂammasome protein produced exclusively in epithelial
cells, results in more severe DSS colitis, because NLRP6inﬂammasome-induced IL-18 production in the epithelial
cell microenvironment controls the growth of Prevotellaceae
species within the crypts. Interestingly, such susceptibility
to colitis is also manifest in coreared normal mice without
NLRP6 abnormalities.15 Similarly, lack of NLRP6 leads to
more severe colorectal cancer, a phenotype that is also
transmissible through microbiota transfer to wild-type
mice.37–39
Even though DSS colitis is caused primarily by disrup-
tion of the epithelium and activation of macrophages and
neutrophils the absence of adaptive immunity, it should be
noted that T-cell responses can aggravate the inﬂammatory
response when both innate and adaptive immunity are
intact. A polarized TH1 response has been observed in acute
colitis whereas a mixed TH1/TH2 response was found in a
chronic form of DSS colitis, achieved by repeated cycles of
DSS administration.8 These T-cell responses result in
effector cytokine production that contributes to the high
levels of tumor necrosis factor-a (TNF-a) and IL-6 produced
by macrophages in both forms of DSS colitis.
As apparent from this discussion, DSS colitis has been
put to good use in the study of many of the attributes of
intestinal inﬂammation. It should not be assumed, however,
that this model is an accurate mimic of human IBD, as
massive epithelial cell damage and wholesale invasion of the
lamina propria by microbes is unlikely to be a primary
mechanism of the human disease. This difference between
DSS colitis and human IBD is also reﬂected in the fact that
chronic DSS colitis is characterized by a mixed T-cell
proinﬂammatory cytokine response, whereas chronic
human IBD is characterized by polarized T-cell responses.
Particularly in the study of primary epithelial cell defects as
a mechanism of human IBD initiation, DSS colitis must be
used with caution as it causes a more widespread and
indiscriminate lesion than is likely to occur in human
disease.Trinitrobenzene Sulfonic Acid Colitis
Intrarectal administration of the haptenating agent
2,4,6-trinitrobenzene sulfonic acid (TNBS) renders colonic
proteins immunogenic to the host immune system and
thereby initiates an mucosal immune response that drives
colitis in susceptible mouse strains.40 Intrarectal TNBS
administration to SJL/J or C57BL/10 mice induces a
transmural colitis mainly driven by a TH1-mediated im-
mune response and characterized by inﬁltration of the
lamina propria with CD4þ T cells, neutrophils, and mac-
rophages as well as development of severe diarrhea,
weight loss, and rectal prolapse.41 As some of these
characteristics resemble features of Crohn’s disease, TNBS
colitis has been widely used in the study of immunologic
aspects relevant to this disease, including cytokine secre-
tion patterns, mechanisms of oral tolerance, and effects of
potential immunotherapies.
It is now well established that cytokine responses are
key elements that control the inﬂammatory mechanisms
underlying IBD. Indeed, it was noted early on that inter-
feron-g (IFN-g) synthesis, in particular, is a characteristic
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inﬂammation observed in this disease.42 Thus, it was
highly signiﬁcant that inﬂammation in TNBS colitis was
associated with elevated levels of IFN-g and that preven-
tion of IFN-g production by anti-IL-12p40 treatment
completely abrogated both nascent and established dis-
ease.41 It was this ﬁnding and those derived from subse-
quent related studies43,44 that paved the way for the
development of a humanized anti-IL-12p40 antibody for
treatment of patients with Crohn’s disease that is reported
to be highly effective in controlling this disease in phase II
and III clinical trials, even in patients who are unrespon-
sive to anti-TNF-a.45,46
Although IL-12p40-neutralizing antibody was originally
intended to block the pathogenic contributions of IL-12, it
was later found that the p40 receptor subunit for IL-12
couples with p19 to form the receptor for IL-23, and that
the latter is essential to the stability of the TH17 response.
47
Several studies were therefore conducted to deﬁne the role
of IL-23 in experimental colitis and to determine whether
IL-12 or IL-23 drives the dominant effector response in
these models.48,49 With respect to TNBS colitis, p19/
mice, which lack IL-23, were unexpectedly found to develop
even more severe colitis than wild-type mice.48 This corre-
lated with the fact that mice with TNBS colitis lacking IL-23
express increased amounts of IL-1248 and that IL-17A pro-
duction can suppress the induction of T-bet, a major tran-
scriptional regulator of IFN-g production.50 Thus, in TNBS
colitis the TH1 response appears to be the dominant effector
response, and the TH17 responses seem to play both effector
as well as regulatory roles in the inﬂammation. As we will
discuss, a somewhat different situation may be obtained in
other models such as adoptive transfer colitis, where the
TH17 responses appear to be dominant although both TH1
and TH17 responses result in cells producing IFN-g (see the
further discussion herein).
In a recent study, TL1a (TNFSF15) was also shown to be
involved in the pathogenesis of TNBS colitis, in that treat-
ment of mice with anti-TL1a completely blocked colitis in-
duction.51 Because abrogation of TH1 cytokine responses
also blocks colitis induction, this ﬁnding implies an under-
lying relation between TL1a and TH1 responses; however, at
the moment, this link is undeﬁned. One possibility based on
the fact that TL1a acts as a T-cell costimulation factor is that
TL1a costimulation is necessary for the generation of the
TH1 response. Another possibility based on TL1a signaling
via DR3 (TNFSFR15) and its capacity to induce IL-1b via the
NLRP3 inﬂammasome is that IL-1b production is a neces-
sary antecedent of the TH1 response. Further work will be
necessary to decide between these as well as other
possibilities.
As alluded to earlier, susceptibility to TNBS colitis and
the type of cytokine response that is induced by TNBS
administration varies signiﬁcantly among mouse strains. In
BALB/c mice, for instance, TNBS colitis has been associated
with TH2-mediated hypertrophy of colonic patches, a
phenotype that is accentuated in the absence of IFN-g.52 A
TH2 component was also observed in C57BL/6 mice deﬁ-
cient in IL-12 and IFN-g.53 Similarly, BALB/c mice are thepreferred strain for induction of chronic TNBS colitis, in
which repeated administration of low doses of TNBS results
in a less intense and more sustained inﬂammation than
obtained in the single, high-dose acute TNBS colitis
described in SJL/J mice. This chronic model has shown that
cytokine expression patterns are dynamic in that they
change as the inﬂammation evolves. Thus, in this setting
inﬂammation is characterized by sequential responses, with
the initial TH1 cell response accompanied by high levels of
IL-12 and IFN-g that is subsequently replaced by a persis-
tent TH17 cell response accompanied by persistent IL-13
and transforming growth factor-b (TGF-b) secretion.54
Such evolution may also be characteristic of human IBD,
at least in part.
Chronic TNBS colitis in BALB/c mice is also associated
with persistent lamina propria ﬁbrosis. This model has
therefore been used to study the potential mechanisms
underlying the intestinal ﬁbrosis that accompanies human
IBD. As shown in the initial report of chronic TNBS colitis,
this model is characterized by increased collagen deposi-
tion as well as production of factors associated with
ﬁbrosis including insulin-like growth factor I (IGF-I), tissue
inhibitor of metalloproteinase-1 (TIMP-1), and TGF-b.55
Subsequent studies explored the mechanism of such
ﬁbrosis and provided evidence that TGF-b production
induced by IL-13, acting via IL-13Ra2, was an initiator of a
ﬁbrotic program that involved early growth response
protein 1 (Egr-1), IGF-I, and myoﬁbroblast production of
collagen.56 Other studies have provided evidence that
ﬁbrosis in this model is induced by substance P acting via
the neurokinin-1 receptor57 and can be opposed by the
antimicrobial peptide cathelicidin.58 Interestingly, ﬁbrosis
in chronic TNBS colitis may also be induced by TL1a, as it
has been shown that this factor also induces ﬁbrogenic
factors and it is said to have direct collagen-inducing
effects on ﬁbroblasts in vitro.59
Despite continued administration of TNBS to BALB/c
mice, chronic intestinal inﬂammation ultimately resolves as
does production of proinﬂammatory IL-17 driving the
inﬂammation. Extensive studies of this resolution of
inﬂammation have determined that persistent IL-13 secre-
tion and accompanying signaling via signal transducer and
activator of transcription 6 (STAT6) results in changes in
glycogen synthase kinase-3b (GSK-3b) phosphorylation and
that this in turn induces expression of IL-10, a regulatory
cytokine. This set of observations suggests that the spon-
taneous waning of human Crohn’s disease inﬂammation
may also be due to glycogen synthase kinase-3b induction of
IL-10.60
Under normal circumstances, when both innate and
adaptive immunity are present, T-cell-derived cytokines,
particularly IFN-g, are critical in TNBS colitis as described
earlier. Studies in SCID and Rag1/ mice, however, have
shown that innate immunity is also involved in the devel-
opment of TNBS colitis because in response to TNBS these
mice develop a colitis that is superﬁcially similar to that
observed in their wild-type counterparts.61 In addition,
production of enabling cytokines such as IL-12 resulting
from stimulation of innate cells by various innate stimuli
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maintenance of the T-cell responses operative in the
inﬂammation. Indeed, inhibition of innate responses by the
NOD2 ligand muramyl dipeptide has been shown to prevent
TNBS colitis.62
The TNBS colitis model has also been used to explore
mechanisms of mucosal homeostasis and the role of NOD2
in the maintenance of such homeostasis. In part, these
studies centered on effects of NOD2 on expansion of reg-
ulatory T cell (Treg) in the lamina propria–bearing latency-
associated protein (LAP), a molecule that binds to TGF-b.
These Treg proliferate in response to the entry of luminal
bacteria or their products into the lamina propria and thus
quell inﬂammation.63 Because NOD2 is an intracellular
bacterial sensor that recognizes the peptidoglycan constit-
uent muramyl dipeptide,64 it was initially assumed that
abnormal Nod2 function would result in uncontrolled in-
vasion of microorganisms into the lamina propria and
associated inﬂammatory responses. On the contrary, NOD2-
deﬁcient mice do not develop spontaneous colonic inﬂam-
mation and are resistant to TNBS colitis. This may reﬂect
increased intestinal permeability to luminal bacteria or
their bacterial products and expansion of regulatory LAPþ
T cells.65 This interpretation is supported by the observa-
tion that adoptive transfer of lamina propria T cells from
NOD2-deﬁcient mice to NOD2-deﬁcient recipient mice—but
not adoptive transfer of LAPþ T-cell-depleted lamina
propria T cells—provided protection from TNBS colitis.
Overall, these studies demonstrated that NOD2 deﬁciency
may paradoxically protect an individual from inﬂammation
by maintaining gut homeostasis under conditions in which
proinﬂammatory inﬂuences arising form other factors are
relatively mild.
It is often forgotten that the TNBS colitis model has
contributed to our understanding of the relation of oral
tolerance mechanisms and to the concept that intestinal
inﬂammation can result from a loss of immune tolerance. In
particular, it was shown early on that oral administration of
TNBS-haptenated colonic proteins before intrarectal instil-
lation of TNBS suppressed colitis and that this suppression
was dependent on TGF-b-producing regulatory T cells.66
Furthermore, it was shown that the development of such
Tregs depended on the production of IL-10, thereby estab-
lishing the latter as a key anti-inﬂammatory cytokine.67 It
was also shown that the feeding of TNBS-haptenated colonic
proteins “cross-protected” mice from the development of
oxazolone colitis (another form of hapten-induced colitis),
albeit to a lesser extent than it protected mice from TNBS
colitis.68 This protection was associated with cells that
exhibited a regulatory phenotype. Overall, these studies
were the ﬁrst to link oral tolerance with the development of
antigen independent Tregs that are capable of controlling
gut inﬂammation.
As our discussion of TNBS colitis has indicated, this
induced model of colitis, while differing in important ways
from human IBD, has served as an important source of in-
formation about the cytokines driving human IBD and the
way to therapy of the human disease. In addition, it remains
a highly useful platform for studying several aspects ofhuman IBD such as the factors guiding its spontaneous
resolution and ﬁbrosis.Oxazolone Colitis
Intrarectal administration of a haptenating agent other
than TNBS was initially expected to give rise to a colitis
similar to TNBS colitis. It therefore came as a surprise that
administration of oxazolone (4-ethoxymethylene-2-phenyl-
2-oxazolin-5-one), a haptenating agent that, like TNBS, in-
duces a delayed skin reaction, elicits colonic inﬂammation
that differs markedly from that caused by TNBS and that
resembles many features of ulcerative colitis rather than
Crohn’s disease.69–71 In particular, administration of a single
dose of oxazolone leads to acute superﬁcial inﬂammation of
the mucosa in the distal colon. This is characterized by
inﬁltration of lymphocytes and neutrophils, lamina propria
edema, and ulcerations.69 A similar but longer-lasting colitis
can be achieved by subcutaneous sensitization with oxazo-
lone before a single-dose intrarectal challenge.70 As in the
case of TNBS colitis, oxazolone colitis is most easily elicited
in SJL/J or C57BL/10 mice whereas C57BL/6 mice are more
resistant to this colitis. Chronic colitis can also be induced in
BALB/c mice by weekly administration of low oxazolone
doses.
The cellular and cytokine responses underlying oxazo-
lone colitis differ markedly from those in TNBS colitis.
Oxazolone colitis is characterized by robust IL-13 produc-
tion originating from lamina propria CD4þ natural killer T
(NKT) cells rather than by conventional CD4þ T cells pro-
ducing IFN-g (Figure 2). Importantly, both IL-13 and NKT
cells are involved in oxazolone colitis, as IL-13 blockade by
an IL-13Ra2-Fc fusion protein prevented colitis, and oxa-
zolone failed to induce colitis in NKT cell-deﬁcient mice.70
These observations may be explained by data showing
that NKT cells are cytotoxic to epithelial cells bearing NKT
cell targets and this cytotoxicity can be augmented by
IL-13.72 In contrast, IL-13 reduced epithelial barrier func-
tion by increasing epithelial cell apoptosis as well as tight
junction permeability via claudin-2 and tricellulin.73–77 This
detrimental effect of IL-13 on epithelial barrier function is
abetted by IL-9, another TH2-like cytokine shown to be
produced during oxazolone colitis.78
The origin of the IL-13 response in oxazolone colitis is as
yet poorly understood although there is some evidence that
it is induced by IL-33 originating from damaged epithelial
cells.79 IL-25 produced by epithelial cells may also
contribute.79 Alternatively, IL-9 may be produced as a result
of T-cell stimulation by IL-13 and TGF-b, both of which are
abundant in oxazolone colitis.
The importance and value of the oxazolone colitis model
is that it resembles human ulcerative colitis not only with
respect to morphology but also with respect to immuno-
pathogenesis. Ulcerative colitis is characterized by in-
creased production of IL-13 and IL-9 and has a lamina
propria inﬁltrate containing NKT cells capable of producing
IL-13.72,78 One important difference between oxazolone
colitis and ulcerative colitis, however, is that in the latter
inﬂammation the NKT cells are so-called type II NKT cells,
Figure 2. Mechanism of oxazolone colitis. Oxazolone colitis is driven by natural killer T (NKT) cells that originate in the
cytokine milieu of epithelial cells subjected to damage by oxazolone as well as hematopoietic cells in the lamina propria. As
shown in the ﬁgure, the NKT cells are activated by glycolipids presented to them in the context of CD1 and then mediate
toxicity via their direct cytotoxic activity directed at target epithelial cells bearing glycolipid antigen. Alternatively, the NKT cells
mediate tissue damage via their production of interleukin-13, a cytokine that has been shown to affect tight junction proteins
and to thereby affect epithelial barrier function.
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teristic of the more familiar type I NKT cells. It has been
shown that the type II NKT cells in ulcerative colitis
recognize and respond to sulfatide glycolipids.80 This sug-
gests that ulcerative colitis may be driven by the epithelial-
cell release of a sulfatide glycolipid that induces NKT cells
and IL-13.Adoptive Transfer Colitis
A major step forward in the development of murine
models of intestinal inﬂammation came with the dis-
covery that adoptive transfer of naïve CD4þ T cells
(CD4þCD45RBhigh T cells) from donor mice into syngeneic
immunodeﬁcient (lymphopenic) SCID or Rag1/ recipient
mice causes a wasting disease and a primarily colonic
inﬂammation that develops 5 to 10 weeks after treatment.
In contrast, transfer of mature CD4þCD45RBlow T cells or
cotransfer of both naïve and mature T cells into the recip-
ient mice did not cause colitis81–84 (Figure 3). This initially
curious and unexplained ﬁnding was then shown to be due
to the fact that the mature T-cell population contains Treg
cells that expand and suppress inﬂammation whereas the
naïve T-cell population lacks such cells. These Treg cells
were ﬁrst characterized as CD4þCD25þ T cells in studies
showing that transfer of CD4þCD45RBlow T cells depleted of
CD4þCD25þ cells into recipient mice induced disease.83
More recently, however, similar studies have shown that
the regulatory cells are the now familiar forkhead box P3þ
(Foxp3þ) Treg cells. Given the crucial role of Treg cells inthis model of colitis and the importance of understanding
the mechanisms that control intestinal immune homeosta-
sis, the cell transfer model has positioned itself as one of the
most widely used models of experimental colitis.
It is now widely accepted that Foxp3þ Treg cells exert
their suppressive function and antagonize effector T cells in
the gut through multiple mechanisms, including the pro-
duction of the cytokines IL-10, TGF-b, and IL-35.85,86 Early
studies highlighted an immunoregulatory role of IL-10 by
showing that administration of anti-IL-10 receptor anti-
bodies or transfer of CD4þ T cells deﬁcient in IL-10 to
Rag1/ hosts resulted in severe colitis.87,88 Later studies
probing the mechanism of IL-10 regulatory activity in the
transfer colitis model showed that Foxp3þ cells deﬁcient in
the IL-10 receptor subunit b (IL-10Rb) failed to protect
recipient mice from colitis and lost their ability to express
Foxp3, suggesting that IL-10R signaling in regulatory cells is
important for the maintenance of their function.89
The role of IL-10 in regulatory T-cell function does not
exclude a role for TGF-b. The latter was demonstrated by
studies showing that protection from colitis by Treg cells
did not occur when TGF-b-deﬁcient CD4þCD25þ T cells
were cotransferred into recipient mice and by the obser-
vation that systemic administration of anti-TGF-b antibody
blocked the ability of CD4þCD25þ T cells to attenuate coli-
tis.90,91 In addition, TGF-b expressed on the surface of
CD4þCD25þ T cells in association with LAP mediated
CD4þCD25þ T-cell suppression in vitro and CD4þLAPþ, but
not CD4þLAP, T cells protected recipient mice from coli-
tis.92 Finally, and perhaps most importantly, naïve T cells
Figure 3. The cell transfer colitis model. Cell transfer colitis is initiated in lymphopenic (SCID or Rag/) mice that are the
recipients of naïve CD45RBhigh T cells, a cell population that cannot be induced to generate regulatory T cells in a timely
fashion to prevent the expansion of effector T cells that mediate inﬂammation. However, if the naïve T cells are transferred in
the company of mature CD45RBlow T cells that already contain regulatory T cells, the latter prevent the development of
inﬂammation. This model thus provides a way of isolating the function of effector cells and regulatory cells.
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negative TGF-b receptor type II could not be suppressed by
Treg cells.93
Although extensively studied, the precise nature of the
inﬂammatory response that regulatory cells suppress in the
transfer colitis model has, at least until recently, been
challenging to deﬁne. The area of controversy concerned the
relative importance of the contributions of the TH1 and
TH17 effector T-cell responses to the colonic inﬂammation.
The earliest studies considered transfer colitis to be a TH1-
mediated model, as it resulted in the development of a large
population of T cells producing IFN-g and TNF-a in the
lamina propria of recipient mice.82 In addition, anti-IFN-g
treatment of the transferred mice ameliorated colitis,82 and
transfer of naïve T cells lacking T-bet, which are unable to
produce IFN-g, failed to induce colitis.94
The discovery of the fact that T cells can differentiate
into TH17 cells under the inﬂuence of IL-23 raised the
possibility that IL-17 (IL-17A and IL-17F) and other cyto-
kines also associated with the TH17 differentiation pathway
such as IL-23, IL-21, and IL-22 might be the main players
driving inﬂammation in transfer colitis rather than IFN-g.
Evidence supporting this possibility quickly became avail-
able and included studies showing that (1) Rag1/
recipient mice also deﬁcient in IL-23p19 did not develop
colitis upon transfer of naïve T cells;49 (2) colitis was not
induced by transfer of naïve T cells lacking the IL-23 re-
ceptor;95 (3) transfer of IL-17A-producing (previously
polarized TH17) antigen-speciﬁc T cells into SCID mice
caused severe colitis that could be prevented by an anti-IL-
23p19 antibody;96 and (4) naïve T cells deﬁcient in RORgt,
the master regulator of TH17 cells, failed to induce colitis in
lymphopenic hosts whereas systemic administration of re-
combinant IL-17A restored susceptibility to colitis.97 These
rather convincing studies establishing the TH17 response as
the major effector pathway in transfer colitis ran up againstthe fact that the number of T cells producing IFN-g is far
greater than those producing IL-17 in the lamina propria of
mice with transfer colitis.98,99 Thus, in spite of strong evi-
dence to the contrary, the TH1 response still appeared to be
the main effector T-cell response underlying this model
of colitis. A similar argument can be made in Crohn’s
disease.100
Recent studies have resolved this apparent contradiction
by showing that TH17 responses that generate IL-17-
producing TH17 cells are inherently plastic and can also
give rise to TH1 cells producing IFN-g. This was initially
evident in studies demonstrating the accumulation of an IL-
17þIFN-gþ T-cell subpopulation in transfer colitis.95,101
More importantly, IL-17F reporter mice were used to
show that, in the absence of TGF-b, IL-23 and IL-12 convert
TH17 cells into “TH1-like” IFN-g-producing cells, and that
transfer of previously polarized IL-17Fþ TH17 cells to
Rag1/ mice resulted in the development of colitis
accompanied by the progressive disappearance of IL-17þ
cells and the appearance of IFN-gþ cells in the inﬂamed
mucosa.102 Finally, linear transformation from TH17 to
apparent TH1 cells via intermediate TH17/TH1 cells was
observed in studies using RORgt reporter mice in which the
initial population of transferred cells could be unequivocally
identiﬁed as TH17 cells.
101 Overall, then, current data sup-
port the view that transfer colitis is in fact largely mediated
by TH1 cells producing IFN-g, but the latter have an atypical
origin in that for the most part they originate indirectly from
a TH17 differentiation pathway depending initially on IL-23
rather than directly from a TH1 differentiation pathway
depending only on IL-12.
As already discussed in relation to TNBS colitis, IL-17
production in transfer colitis can paradoxically suppress
inﬂammation by blocking the development of TH1 cells
producing IFN-g, which has for greater proinﬂammatory
potential. Consistent with this, transfer of naïve T cells from
March 2015 Experimental Models of IBD 163IL-17A KO mice to Rag1/ mice induces a more aggressive
wasting disease with earlier onset and higher levels of IFN-g
relative to disease following transfer of wild-type naïve T
cells.50 These ﬁndings were explained by showing that TH1
cells express IL-17 receptors, and that IL-17A signaling
through those receptors decreases TH1 differentiation by
inhibiting production of T-bet, a key transcriptional regu-
lator of IFN-g production. Interestingly, this interference
between potentially colitogenic TH1 and TH17 cells may be
bidirectional. Studies using parabiotic mice in whom TH1
and TH17 colitis was induced separately, before surgery and
effector cells mixing, showed that colitogenic responses
mediated by TH1 cells or TH17 cells are in competition and
down-modulate one other.98
The TH17 T-cell differentiation pathway—or, more spe-
ciﬁcally, a major component of this pathway, IL-23—has
also be shown to negatively inﬂuence regulatory T-cell re-
sponses. In initial studies supporting this idea, it was
demonstrated that IL-23p19-deﬁcient mice exhibit an
increased number of Treg cells in the colon;103 in addition,
transfer of naïve T cells to Rag1/ mice deﬁcient in IL-
23p19, which might be expected to not induce colitis
because of lack of IL-17, does in fact induce colitis in situ-
ations where recipient mice could not mount a regulatory
T-cell response due to lack of IL-10, TGF-b, or CD4þFoxp3þ
T cells.103 Finally, and most convincingly, the numbers of
Foxp3þ Treg cells in the colon of Rag1/ recipient mice
reconstituted with IL-23 receptor-deﬁcient T cells are
increased.95 Taken together, these ﬁndings demonstrate
rather unequivocally that IL-23 production favors the
development of inﬂammation by mediating TH17 effector
cell responses and by inhibiting Foxp3þ regulatory T-cell
differentiation.
Recent studies have provided data supporting the idea
that the described negative effect of IL-23 on regulatory
T-cell development is not unopposed. In particular, IL-33, a
cytokine constitutively expressed by epithelial cells in
response to tissue damage, enhances regulatory T-cell
stability and function in transfer colitis.104 Moreover, Treg
cells that lack the IL-33 receptor (ST2) lost their Foxp3
expression over time and were unable to protect mice from
adoptive transfer colitis.104 Consistent with previous
observations establishing an important role for the tran-
scription factor GATA-3 in regulatory T-cell function,105,106
it was shown that ST2-expression in Tregs was largely
dependent on GATA-3.104 Overall, then, Treg activity in
transfer colitis is under the yin of IL-23 and the yang of
IL-33, which operate in opposing fashions to regulate
inﬂammation. A similar regime may govern Crohn’s disease
because IL-33 has also been found in inﬂamed tissues of IBD
patients.107–111
Whereas the main effect of IL-23 in relation to the in-
duction of TH17 T-cell differentiation is to stabilize and
ensure the survival of IL-17 cells initially induced by TGF-b
and IL-6 or IL-1b,112–114 this cytokine may also have other
effects that inﬂuence inﬂammation in transfer colitis. Along
these lines, there is some evidence that IL-23 induces IL-17-
producing cells with more proinﬂammatory potential (such
as TH17 cells) that do not coproduce IL-10.
114–116 Inaddition, there is emerging evidence that transfer colitis,
presumably as a result of IL-23 production, is accompanied
by increased granulocyte-macrophage colony-stimulating
factor117 and IL-5 production (personal communication
from F. Powrie), both cytokines that can profoundly affect
the nature of the inﬂammatory inﬁltrate in transfer colitis.
Finally, it is important to mention that although it is
primarily linked to TH17 T-cell development, IL-23 induces
innate lymphoid cells, a recently discovered population
shown to express IL-17, IL-22, and IFN-g and to mediate
intestinal inﬂammation in models of innate colitis, particu-
larly when they produce IFN-g.118 There is also some
evidence that small numbers of these cells accumulate in the
inﬂamed mucosa of Crohn’s disease patients, and it has been
postulated that these cells play a role in the initiation of
Crohn’s disease.119
As in most other colitis models,120–123 adoptive trans-
fer colitis does not develop in germ-free mice.124 This
important fact suggests that, as in DSS colitis, transfer
colitis is marked by a change in epithelial barrier function
and that it is the entry of either commensal bacteria or
bacterial components into the lamina propria that then
drives the inﬂammation. However, there is no evidence
that a particular subset of bacterial organisms serve as
colitogenic organisms in transfer colitis (or indeed in
human IBD); instead, it is likely that a large and diverse
subset of organisms with particular ability to penetrate an
impaired epithelial layer act together to induce inﬂam-
mation.125 It should also be noted that commensal bacteria
are thought to contribute to intestinal immune homeo-
stasis and confer protection from the development of
inﬂammation. This is nicely demonstrated by the fact that
transfer colitis conducted in immunodeﬁcient mice colo-
nized with Helicobacter hepaticus results in a severe colitis
that is abrogated by co-colonization with Bacteroides
fragilis.126 The observed protective activity of B. fragilis
requires the molecule polysaccharide A (PSA); co-
colonization with a mutant B. fragilis lacking PSA failed
to ameliorate colitis whereas oral administration of PSA
reduced the disease. Colonization of mice with B. fragilis
was later shown to facilitate Treg differentiation and IL-10
production.127 Other commensal bacteria from clusters IV
and XIVa of the Clostridium genus have also been shown to
induce accumulation of Treg in the colon and confer
resistance to colitis in mice.128 There is some evidence that
this occurs via bacterial secretion of short-chain fatty acids
that induce epigenetic changes favoring Foxp3þ T-cell
development.129
This overview of the cell transfer model reminds us of
the extraordinary contributions of this model to the study of
intestinal inﬂammation. In particular, it has been used with
great effect to deﬁne the role of regulatory cells in such
inﬂammation and to thus establish the fact that mucosal
homeostasis depends on a balance between mucosal
proinﬂammatory effector function and anti-inﬂammatory
regulatory function. This said, it cannot be assumed that a
model that depends on cell expansion in a lymphopenic host
mimics human IBD. Further, it is yet to be proven that a
qualitative or quantitative defect in regulatory cell
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to disease pathogenesis.130
Interleukin-10 Knockout Mice
One of the earliest models of intestinal inﬂammation was
that identiﬁed in mice with IL-10 deﬁciency.131 This model
continues to have great value given the important anti-
inﬂammatory function of this cytokine, already discussed
in relation to other experimental models of colitis. In addi-
tion, it is now known that genetic polymorphisms at the IL-
10 locus confer increased risk of both ulcerative colitis
and Crohn’s disease132,133 and, perhaps more importantly a
familial form of early onset Crohn’s disease has been iden-
tiﬁed that is due to homozygous mutations in subunits of
the IL-10 receptor: IL10RA and IL10RB.134
Mice with targeted deletion of IL-10 (Il10/) develop
spontaneous inﬂammation of the colon characterized by the
presence of an inﬂammatory inﬁltrate made up of lympho-
cytes, macrophages, and neutrophils.131 The inﬂammation is
initially driven by a proinﬂammatory TH1 T-cell response
and as such is ameliorated by systemic administration of
anti-IL-12p40, and to a lesser extent anti-IFN-g.135 How-
ever, for as yet unexplained reasons, the production of IL-12
and IFN-g decreases over time and is to some extent su-
perseded by progressive increases in the production of the
TH2 cytokines IL-4 and IL-13.
136 Blimp1/ and Il10rb/
mice, which also have a defect in IL-10 production or
responsiveness, recapitulate the phenotype of Il10/ mice
and thus support the presumption that lack of IL-10 pro-
duction is directly responsible for the intestinal inﬂamma-
tion in such mice.137,138 In addition, deletion of IL-10 in all
T cells or speciﬁcally in Foxp3þ Treg cells also results
in spontaneous colitis, indicating that IL-10 derivedfrom these cells is important to the maintenance of gut
homeostasis.139,140
Stimulation of the mucosal immune system by
commensal microﬂora is critical for the development of
colitis in IL-10-deﬁcient mice, as the latter do not develop
colitis in a germ-free environment but do develop colitis
several weeks after transfer from a germ-free environment
to a pathogen-free environment. Such stimulation is most
likely dependent on the sensing of commensal microbes by
Toll-like receptors, as MyD88 deﬁciency in colonic mono-
nuclear phagocytes completely prevents colitis.121,141,142 It
should be noted, however, that onset of inﬂammation in
IL-10-deﬁcient mice can be initiated by administration of
piroxicam, an nonsteroidal anti-inﬂammatory drug that in-
duces oxidative stress.143 The mechanism of this effect is
unknown, but it could be associated with activation of the
NLRP3 inﬂammasome, which is sensitive to such stress.
A related observation is that mice lacking both IL-10 and
PTEN (phosphatase and tensin homolog on chromosome
10), a phosphatase that regulates cell proliferation and
receptivity to TLR stimulation, develop colitis more rapidly
and with greater severity than IL-10/ mice and also form
colonic tumors.144 This greater susceptibility to colitis is
reversed in mice lacking the ability to respond to TLR4
stimulation, indicating that the lack of PTEN is operating, at
least in part, by increasing responsiveness to TLR stimula-
tion. An interesting additional observation is that PTEN/
IL-10 deﬁcient mice have a fecal microbiome that contains
increased amounts of Bacteroides organisms. suggesting
that the lack of PTEN may also inﬂuence disease patho-
geneses via effects on the microbiome.
The ﬁnding that TLR ligand stimulation is critical for
induction of colitis in IL-10-deﬁcient mice suggests thatFigure 4. The ﬁve experi-
mental models of
inﬂammation discussed
in the text are grouped
here in relation to their
varying inducing condi-
tions. To the right of the
individual mouse models
are the major mucosal im-
mune functions/therapies/
diseases that are best
addressed using these
respective models.
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10 is a major cause of inﬂammation in such mice. This
possibility is supported by a recent study showing that
failure of intestinal resident macrophages to respond to
IL-10 (because of lack of IL-10 receptor expression) led to
the development of a proinﬂammatory macrophage migra-
tory proﬁle essential for the development of spontaneous
colitis.145 In addition, a related report showed that IL-10
sensing by anti-inﬂammatory macrophages was important
for their ability to establish mucosal homeostasis.146 Finally,
monocyte-derived macrophages from early onset Crohn’s
disease patients harboring loss of function mutations in
IL10RA and IL10RB also exhibit impaired differentiation and
function.146 However, these studies should not be inter-
preted to indicate that macrophage dysfunction is the only
abnormality accounting for inﬂammation in IL-10 deﬁ-
ciency, as Treg cells also depend on IL-10 and thus Treg cell
dysfunction likely plays an important role.
Conclusions
The ﬁve models of intestinal inﬂammation we have dis-
cussed (Figure 4) provide a survey of the extensive and
sometimes complex mechanisms operative in the genesis of
intestinal inﬂammation and pathogenesis of IBD. Table 1
brieﬂy describes a number of additional models; at our pre-
sent level of understanding, these models usually focus on
particular rather than general abnormalities andmechanisms
of gut inﬂammation. Finally, it is worth noting that even
though the study of models of inﬂammation is no longer in its
infancy, an enormous body of knowledge has yet to be har-
vested from the application of this biologic methodology.References
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